Lexicon Pharmaceuticals' Q1 2025 highlights include a transformative Novo Nordisk partnership, Phase 3 plans for pilavapadin in DPNP, and refocused ...

Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with ...

Home > Press release: Study launched to identify new ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 6 undervalued stocks in the Pharmaceuticals industry for Tuesday, May 13, 2025. Let’s take ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

A single intradiscal injection of allogeneic NP reduced chronic lumbar discogenic pain and improved function at 12 months, ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2b Trial of Halneuron® in CINP underway; Interim Results ...

You would be amazed to know that only 2 percent of the population has the INFJ personality type as advocated by the Myers and Briggs 16 Personality TypeAre you one of those who find it hard to relate ...